Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis

Dolezelova, E. and Stein, E. and Derosa, G. and Maffioli, P. and Nachtigal, P. and Sahebkar, A. (2017) Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. British Journal of Clinical Pharmacology, 83 (7). pp. 1380-1396.

[img] Text
Effect of ezetimibe on plasma adipokines a systematic review and meta analysis.pdf

Download (1MB)


Aims: Statins are known to influence the status of adipokines, which play a key role in the pathophysiology of cardiometabolic diseases. As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear, the aim of the present study was to investigate this through a meta-analysis of controlled trials. Methods: A systematic review was performed, followed by a bibliographic search in PubMed, Medline, SCOPUS, Web of Science and Google Scholar databases. Quantitative data synthesis was performed using a fixed- or random-effects model (based on the level of interstudy heterogeneity) and the generic inverse variance weighting method. Effect sizes were expressed as standardized mean difference (SMD) and 95 confidence interval (CI). Results: Meta-analysis of 23 controlled trials did not suggest any significant effect of adding ezetimibe on top of statin therapy on plasma concentrations of adiponectin (SMD 0.34, 95 CI –0.28, 0.96; P = 0.288), leptin (SMD –0.75, 95 CI: –2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD –1.06, 95 CI: –2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95 CI: –0.08, 0.67; P = 0.124). However, significantly greater reductions in plasma concentrations of tumour necrosis factor α (TNF-α) (SMD –0.48, 95 CI –0.87, −0.08; P = 0.018) were achieved with ezetimibe/statin combination therapy. Conclusions: The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-α in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-α-lowering effect. © 2017 The British Pharmacological Society

Item Type: Article
Additional Information: Cited By :7 Export Date: 16 February 2020 CODEN: BCPHB Correspondence Address: Sahebkar, A.; Biotechnology Research Center, Mashhad University of Medical SciencesIran; email: sahebkara@mums.ac.ir
Uncontrolled Keywords: adipose tissue cytokine ezetimibe pleiotropic statin tumour necrosis factor α adipocytokine atorvastatin hydroxymethylglutaryl coenzyme A reductase inhibitor interleukin 6 leptin mevinolin plasminogen activator inhibitor 1 rosuvastatin simvastatin tumor necrosis factor adiponectin ADIPOQ protein, human hypocholesterolemic agent IL6 protein, human SERPINE1 protein, human add on therapy Article blood level controlled clinical trial (topic) drug effect effect size human meta analysis monotherapy priority journal randomized controlled trial (topic) systematic review atherosclerosis blood combination drug therapy comparative study procedures Anticholesteremic Agents Drug Therapy, Combination Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Interleukin-6 Randomized Controlled Trials as Topic Tumor Necrosis Factor-alpha
Subjects: WH Hemic and Lymphatic System
QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib3 lib3
Date Deposited: 16 May 2020 21:58
Last Modified: 16 May 2020 21:58
URI: http://eprints.mums.ac.ir/id/eprint/16796

Actions (login required)

View Item View Item